Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Qiagen Buys DxS, Boasts "Deepest" Personalized Medicine Testing Pipeline

This article was originally published in The Gray Sheet

Executive Summary

Qiagen is boasting the "deepest" pipeline of molecular diagnostics for personalized medicine after acquiring test maker DxS for $95 million, plus up to $35 million in milestone payments

You may also be interested in...



News In Brief

Cardinal Health makes $2 billion acquisition; partnerships in diagnostics, mobile health announced; more news.

Qiagen Buys Cellestis For QuantiFeron “Pre-Molecular” Diagnostics

Qiagen plans to incorporate Cellestis’ QuantiFeron “pre-molecular” diagnostics technology into its own automated and mobile testing platforms after acquiring the firm for $355 million in a deal announced April 3.

Qiagen Buys Cellestis For QuantiFeron “Pre-Molecular” Diagnostics

Qiagen plans to incorporate Cellestis’ QuantiFeron “pre-molecular” diagnostics technology into its own automated and mobile testing platforms after acquiring the firm for $355 million in a deal announced April 3.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT027971

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel